68 related articles for article (PubMed ID: 31371519)
1. Correction to "Long QT2 Mutation on the Kv11.1 Ion Channel Inhibits Current Activity by Ablating a Protein Kinase Cα Consensus Site".
Mol Pharmacol; 2019 Sep; 96(3):377. PubMed ID: 31371519
[No Abstract] [Full Text] [Related]
2. Long QT2 mutation on the Kv11.1 ion channel inhibits current activity by ablating a protein kinase Cα consensus site.
Donovan AJ; Lansu K; Williams JG; Denning MF; Gentile S
Mol Pharmacol; 2012 Sep; 82(3):428-37. PubMed ID: 22653970
[TBL] [Abstract][Full Text] [Related]
3. PKD Phosphorylation as Novel Pathway of KV11.1 Regulation.
Steffensen AB; Bomholtz SH; Andersen MN; Olsen JV; Mutsaers N; Lundegaard PR; Lundby A; Schmitt N
Cell Physiol Biochem; 2018; 47(4):1742-1750. PubMed ID: 29949809
[TBL] [Abstract][Full Text] [Related]
4. Rescue of protein expression defects may not be enough to abolish the pro-arrhythmic phenotype of long QT type 2 mutations.
Perry MD; Ng CA; Phan K; David E; Steer K; Hunter MJ; Mann SA; Imtiaz M; Hill AP; Ke Y; Vandenberg JI
J Physiol; 2016 Jul; 594(14):4031-49. PubMed ID: 26958806
[TBL] [Abstract][Full Text] [Related]
5. Association of 14-3-3 proteins to beta1-adrenergic receptors modulates Kv11.1 K+ channel activity in recombinant systems.
Tutor AS; Delpón E; Caballero R; Gómez R; Núñez L; Vaquero M; Tamargo J; Mayor F; Penela P
Mol Biol Cell; 2006 Nov; 17(11):4666-74. PubMed ID: 16914520
[TBL] [Abstract][Full Text] [Related]
6. Novel intracellular transport-refractory mutations in KCNH2 identified in patients with symptomatic long QT syndrome.
Fukumoto D; Ding WG; Wada Y; Fujii Y; Ichikawa M; Takayama K; Fukuyama M; Kato K; Itoh H; Makiyama T; Omatsu-Kanbe M; Matsuura H; Horie M; Ohno S
J Cardiol; 2018 Apr; 71(4):401-408. PubMed ID: 29146210
[TBL] [Abstract][Full Text] [Related]
7. hERG1/Kv11.1 activation stimulates transcription of p21waf/cip in breast cancer cells via a calcineurin-dependent mechanism.
Perez-Neut M; Rao VR; Gentile S
Oncotarget; 2016 Sep; 7(37):58893-58902. PubMed ID: 25945833
[TBL] [Abstract][Full Text] [Related]
8. Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism.
Anderson CL; Delisle BP; Anson BD; Kilby JA; Will ML; Tester DJ; Gong Q; Zhou Z; Ackerman MJ; January CT
Circulation; 2006 Jan; 113(3):365-73. PubMed ID: 16432067
[TBL] [Abstract][Full Text] [Related]
9. Molecular Cloning and Functional Expression of the Equine K+ Channel KV11.1 (Ether à Go-Go-Related/KCNH2 Gene) and the Regulatory Subunit KCNE2 from Equine Myocardium.
Pedersen PJ; Thomsen KB; Olander ER; Hauser F; Tejada Mde L; Poulsen KL; Grubb S; Buhl R; Calloe K; Klaerke DA
PLoS One; 2015; 10(9):e0138320. PubMed ID: 26376488
[TBL] [Abstract][Full Text] [Related]
10. Compounds commonly used in equine medicine inhibits the voltage-gated potassium channel K
Calloe K; Rognant S; Friis S; Shaughnessy C; Klaerke DA; Trachsel D
Res Vet Sci; 2019 Apr; 123():239-246. PubMed ID: 30685649
[TBL] [Abstract][Full Text] [Related]
11. Effects of Temperature on Heteromeric Kv11.1a/1b and Kv11.3 Channels.
Mauerhöfer M; Bauer CK
Biophys J; 2016 Aug; 111(3):504-523. PubMed ID: 27508435
[TBL] [Abstract][Full Text] [Related]
12. Large-scale mutational analysis of Kv11.1 reveals molecular insights into type 2 long QT syndrome.
Anderson CL; Kuzmicki CE; Childs RR; Hintz CJ; Delisle BP; January CT
Nat Commun; 2014 Nov; 5():5535. PubMed ID: 25417810
[TBL] [Abstract][Full Text] [Related]
13. Kv11.1 channel subunit composition includes MinK and varies developmentally in mouse cardiac muscle.
Wang X; Xu R; Abernathey G; Taylor J; Alzghoul MB; Hannon K; Hockerman GH; Pond AL
Dev Dyn; 2008 Sep; 237(9):2430-7. PubMed ID: 18729211
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of drug interaction with the Kv11.1 potassium channel.
Hill AP; Perrin MJ; Heide J; Campbell TJ; Mann SA; Vandenberg JI
Mol Pharmacol; 2014 May; 85(5):769-76. PubMed ID: 24586056
[TBL] [Abstract][Full Text] [Related]
15. Preclinical study of a Kv11.1 potassium channel activator as antineoplastic approach for breast cancer.
Fukushiro-Lopes DF; Hegel AD; Rao V; Wyatt D; Baker A; Breuer EK; Osipo C; Zartman JJ; Burnette M; Kaja S; Kouzoukas D; Burris S; Jones WK; Gentile S
Oncotarget; 2018 Jan; 9(3):3321-3337. PubMed ID: 29423049
[TBL] [Abstract][Full Text] [Related]
16. The role of CAV3 in long-QT syndrome: clinical and functional assessment of a caveolin-3/Kv11.1 double heterozygote versus caveolin-3 single heterozygote.
Hedley PL; Kanters JK; Dembic M; Jespersen T; Skibsbye L; Aidt FH; Eschen O; Graff C; Behr ER; Schlamowitz S; Corfield V; McKenna WJ; Christiansen M
Circ Cardiovasc Genet; 2013 Oct; 6(5):452-61. PubMed ID: 24021552
[TBL] [Abstract][Full Text] [Related]
17. Adrenergic regulation of the rapid component of delayed rectifier K+ current: implications for arrhythmogenesis in LQT2 patients.
Zankov DP; Yoshida H; Tsuji K; Toyoda F; Ding WG; Matsuura H; Horie M
Heart Rhythm; 2009 Jul; 6(7):1038-46. PubMed ID: 19419905
[TBL] [Abstract][Full Text] [Related]
18. A novel life-threatening mutation in long QT2 syndrome.
Biernacka E; Szperl M; Kosiec A; Roszczynko M; Hoffman P
Kardiol Pol; 2015; 73(11):1097-100. PubMed ID: 25987402
[TBL] [Abstract][Full Text] [Related]
19. The combined activation of K
Pillozzi S; D'Amico M; Bartoli G; Gasparoli L; Petroni G; Crociani O; Marzo T; Guerriero A; Messori L; Severi M; Udisti R; Wulff H; Chandy KG; Becchetti A; Arcangeli A
Br J Cancer; 2018 Jan; 118(2):200-212. PubMed ID: 29161243
[TBL] [Abstract][Full Text] [Related]
20. Allosteric Modulation of Kv11.1 (hERG) Channels Protects Against Drug-Induced Ventricular Arrhythmias.
Yu Z; Liu J; van Veldhoven JP; IJzerman AP; Schalij MJ; Pijnappels DA; Heitman LH; de Vries AA
Circ Arrhythm Electrophysiol; 2016 Apr; 9(4):e003439. PubMed ID: 27071825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
